Inspire Medical Systems delivered a better-than-expected Q3, with EPS of $0.14 and revenue of $206.7 million, topping estimates. The company narrowed its FY2026 guidance for adjusted EPS and sales, signaling discipline amid ongoing headwinds but potential for growth in 2027 as physician coding dynamics improve. The result and optimistic commentary prompted modest pre-market upside and higher price targets from Baird and Piper Sandler.
INSP delivered a solid Q2 beat with EPS and revenue above expectations and raised FY2026 guidance. The updates imply stronger demand and improving profitability as reimbursement dynamics evolve. Analysts lifted targets on INSP, supporting a cautiously bullish setup into the next several quarters.
INSP stock surged due to a Medicare reimbursement increase announcement. Analyst upgrade from 'Hold' to 'Buy' with a $110 target price. Stock is down 38% YTD, presenting volatility concerns. High valuation ratios indicate premium pricing for growth. Financially strong but uncertain profitability amidst substantial growth investment.
Stifel upgrades INSP to Buy, raising price target to $110. Inspire Medical sees a 50% reimbursement increase for its Inspire V implant. Advertising spending rose 56% in Q3, boosting procedure awareness. Despite a 41% drop in 2025, 10 out of 18 analysts recommend Buy. Weight-loss drugs pose risks but current valuation reflects concerns.
INSP broke below the Cakra, indicating potential long-term bearishness. The stock has declined around 50% since its breakdown. Recovery is unlikely until the Guna Triads form around May 2028. Allegations of securities law violations add further risk to INSP. Investors are advised to avoid INSP until a constructive setup emerges.
